Cargando…

Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial

BACKGROUND: Rheumatoid arthritis (RA), a chronic systemic autoimmune disease, is characterized by synovitis and progressive damage to the bone and cartilage of the joints, leading to disability and reduced quality of life. This study was a randomized clinical trial comparing the outcomes between wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Mengyan, Xue, Yu, Du, Fang, Ma, Lili, Lu, Liang-jing, Jiang, Lindi, Tao, Yi-Li, Yang, Chengde, Shi, Hui, Liu, Honglei, Cheng, Xiaobing, Ye, Junna, Su, Yutong, Zhao, Dongbao, Dai, Sheng-Ming, Teng, Jialin, Hu, Qiongyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106157/ https://www.ncbi.nlm.nih.gov/pubmed/36848153 http://dx.doi.org/10.1097/CM9.0000000000002561

Ejemplares similares

Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China
por: Hu, Qiongyi, et al.
Publicado: (2020)

The clinical pattern differentiates ANCA-positive infective endocarditis patients from ANCA-associated vasculitis patients: a 23 years’ retrospective cohort study in China and follow-ups
por: Wang, Fan, et al.
Publicado: (2022)

Anti-SIRT1 autoantibody is elevated in ankylosing spondylitis: a potential disease biomarker
por: Hu, Qiongyi, et al.
Publicado: (2018)

Methylenetetrahydrofolate Reductase 677T Allele Is a Risk Factor for Arterial Thrombosis in Chinese Han Patients with Antiphospholipid Syndrome
por: Tang, Zihan, et al.
Publicado: (2022)

Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome
por: Zhou, Zhuochao, et al.
Publicado: (2021)

Association of the Leukocyte Immunoglobulin‐like Receptor A3 Gene With Neutrophil Activation and Disease Susceptibility in Adult‐Onset Still’s Disease
por: Wang, Mengyan, et al.
Publicado: (2021)

Cysteine-Rich Angiogenic Inducer 61 Serves as a Potential Serum Biomarker for the Remission of Adult-Onset Still's Disease
por: Su, Yutong, et al.
Publicado: (2019)

Interleukin-37 is increased in adult-onset Still’s disease and associated with disease activity
por: Chi, Huihui, et al.
Publicado: (2018)

Cytomegalovirus Infection May Trigger Adult-Onset Still's Disease Onset or Relapses
por: Jia, Jinchao, et al.
Publicado: (2019)

“Non-criteria” antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort
por: Liu, Tingting, et al.
Publicado: (2020)

Circulating Neutrophil Extracellular Traps Signature for Identifying Organ Involvement and Response to Glucocorticoid in Adult-Onset Still’s Disease: A Machine Learning Study
por: Jia, Jinchao, et al.
Publicado: (2020)

Neutrophil-derived lipocalin-2 in adult-onset Still’s disease: a novel biomarker of disease activity and liver damage
por: Jia, Jinchao, et al.
Publicado: (2020)

Urinary Proteomics Identifying Novel Biomarkers for the Diagnosis of Adult-Onset Still’s Disease
por: Sun, Yue, et al.
Publicado: (2020)

Anti-Tyro3 IgG Associates with Disease Activity and Reduces Efferocytosis of Macrophages in New-Onset Systemic Lupus Erythematosus
por: Zhou, Zhuochao, et al.
Publicado: (2020)

Clinical characteristics of infective endocarditis in patients with antineutrophil cytoplasmic antibody or antiphospholipid antibody: a retrospective study in Shanghai
por: Zhou, Zhuochao, et al.
Publicado: (2020)

Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients
por: Shi, Hui, et al.
Publicado: (2017)

Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still’s disease
por: Hu, Qiongyi, et al.
Publicado: (2019)

Serum sTREM-1 in adult-onset Still’s disease: a novel biomarker of disease activity and a potential predictor of the chronic course
por: Wang, Zhihong, et al.
Publicado: (2020)

Total metabolic lesion volume of lymph nodes measured by (18)F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still’s disease
por: Wan, Liyan, et al.
Publicado: (2021)

Fucosylation of anti-dsDNA IgG1 correlates with disease activity of treatment-naïve systemic lupus erythematosus patients
por: Han, Jing, et al.
Publicado: (2022)

Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases
por: Teng, Jialin, et al.
Publicado: (2020)

Differential diagnostic performance of PET/CT in adult-onset still’s disease and lymphoma: a retrospective pilot study
por: Wan, Liyan, et al.
Publicado: (2022)

Current and emerging biological therapy in adult-onset Still’s disease
por: Ma, Yuning, et al.
Publicado: (2021)

Pregnancy Outcomes in Patients With Adult-Onset Still's Disease: A Cohort Study From China
por: Wang, Zhihong, et al.
Publicado: (2020)

Value of the HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the inflammatory myopathy population
por: Shi, Yunjing, et al.
Publicado: (2023)

Cytokine Storm in Coronavirus Disease 2019 and Adult-Onset Still’s Disease: Similarities and Differences
por: Meng, Jianfen, et al.
Publicado: (2021)

COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study
por: Pan, Haoyu, et al.
Publicado: (2022)

Fate of Lymphocytes after Withdrawal of Tofacitinib Treatment
por: Piscianz, Elisa, et al.
Publicado: (2014)

A Cohort Study of Liver Involvement in Patients With Adult-Onset Still's Disease: Prevalence, Characteristics and Impact on Prognosis
por: Chi, Huihui, et al.
Publicado: (2020)

Ferritin triggers neutrophil extracellular trap-mediated cytokine storm through Msr1 contributing to adult-onset Still’s disease pathogenesis
por: Jia, Jinchao, et al.
Publicado: (2022)

PReS-FINAL-2338: Fate of lymphocytes after withdrawal of Tofacitinib treatment
por: Tommasini, A, et al.
Publicado: (2013)

Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
por: Fleischmann, Roy, et al.
Publicado: (2022)

Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study
por: Paroli, Marino, et al.
Publicado: (2023)

Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib
por: Inanc, Nevsun, et al.
Publicado: (2023)

CD36 mediates SARS-CoV-2-envelope-protein-induced platelet activation and thrombosis
por: Tang, Zihan, et al.
Publicado: (2023)

Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis
por: Kim, Joon Wan, et al.
Publicado: (2013)

Fracture in clinical studies of tofacitinib in rheumatoid arthritis
por: Hansen, Karen E., et al.
Publicado: (2022)

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6
por: van Vollenhoven, Ronald F., et al.
Publicado: (2018)

Ultrasound response to tofacitinib in patients with rheumatoid arthritis: Data from a multicenter 24 weeks prospective study
por: Germanò, Giuseppe, et al.
Publicado: (2022)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_82k26ec5lk6jr43j0v2bp8t40d